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cancer staging or surveillance in asymptomatic patients. Further studies are needed to 
characterize patients’ typology who deserve intensive staging and follow-up 
procedures.
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OBJECTIVES: Radiotherapy with protons is a promising new treatment modality, for 
which adoption decisions are being made worldwide. However, the investment costs 
of proton therapy (PT) are high (roughly c90 million) and limited clinical evidence is 
available. Also, previous studies have indicated that PT may be cost-effective, but show 
considerable decision uncertainty. Consequently, it is unclear whether we should 
adopt PT now, or wait for more information. Adoption involves a risk of facing high 
sunk costs, while delay may impose opportunity losses because patients receive sub-
optimal treatment. Real options analysis (ROA), a technique originating from ﬁ nancial 
economics, assists in making this trade-off. METHODS: We examined whether to 
adopt PT, as compared to stereotactic body radiotherapy, in the treatment of stage I 
non-small cell lung cancer (NSCLC). Three options are available: adopt without 
further research (AN); adopt and undertake a trial (AT); or delay and undertake a 
trial (DT). The decision depends on the expected net gain of each option, which is 
calculated by subtracting its total costs from its expected beneﬁ ts. RESULTS: The 
expected net gain of at and DT were positive, indicating that we should not decide to 
adopt without further research (AN). Up to a sample size of 1000 patients, the 
expected net gain of at was higher than DT, indicating that the best option was to 
adopt and trial. The expected net gain of at was highest for a sample size of 450 
patients, which is thus considered the optimal sample size. CONCLUSIONS: Based 
on these results, we recommend to adopt PT in the treatment of stage I NSCLC, and 
to perform a trial with 450 patients. We have shown that ROA provides a transparent 
method of weighing the costs and beneﬁ ts of all available options, to assist in decision-
making upon new and expensive technologies.
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OBJECTIVES: During disease monitoring of patients with CML, for patients with a 
complete response, residual leukemia can be assessed by real-time quantitative 
polymerase chain reaction (RQ-PCR). There are several “home-brew” and commer-
cially available BCR-ABL gene transcript detection methodologies in use, each 
requiring internal validation for the speciﬁ c laboratory and giving rise to laboratory-
speciﬁ c data. Harmonization of results according to an international scale is under-
way, but use is limited for several technical reasons. Information is required for 
decision makers on the accuracy and reproducibility of the tests and their costs 
and cost-effectiveness. The objective of this study was to assess the quantity and 
quality of such information. METHODS: English language systematic literature 
review on the intra- and inter-laboratory variability for BCR-ABL molecular monitor-
ing testing, inter-rater reliability across manual assays and the costs and cost-effec-
tiveness of molecular testing in CML. RESULTS: From 88 papers retrieved for detailed 
analysis, we found no studies which conducted a repeated test procedure on the same 
patient sample using the same technical approach in the same laboratory. There are 
a large number of studies which have compared alternative approaches using the same 
patient sample in molecular monitoring in the same laboratory. Several well-conducted 
studies have examined the variability of results from different laboratories in con-
trolled environments. We found no studies which compared inter-rater reliability or 
examined the costs or cost-effectiveness of molecular testing in CML. CONCLU-
SIONS: There is a reasonable body of evidence on certain aspects of analytical validity 
for CML molecular testing, but other aspects of analytical validity and the costs and 
economics of molecular diagnostics in CML appear to be an unresearched area. 
Testing variability has potentially serious implications for patient outcomes and more 
information for decision-makers to assess relative costs and cost-effectiveness is 
required.
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OBJECTIVES: The oncology market has become one of the major focus areas for 
pharmaceutical and biotech ﬁ rms. As of March 2009, 15,752 of 39,747 Phase I, II, 
and III trials listed on clinicaltrials.gov were related to cancer (approximately 40%). 
This large interest in oncology stems from market success of cancer therapies launched 
in the past decade and the existence of high unmet need to treat different types of 
cancers. As the number of FDA approved cancer therapies increases, there is a need 
to understand treatment patterns of these cancer drugs. METHODS: To understand 
the trends in usage and sales of cancer therapies, we analyzed the US market (sales 
and prescription) 2005–2008 data for all FDA-approved cancer drugs. Drugs were 
categorized as targeted cancer therapies, chemotherapies, monoclonal antibodies, 
small molecules, branded, and generics. RESULTS: During the past 5 years, the usage 
of both targeted cancer therapies and chemotherapy drugs has increased by high 
double digit rates. From 2005 to 2008, the total prescriptions for targeted cancer 
therapies and chemotherapies increased by 66% and 30%, respectively. While the 
sales of both types of these drugs are expanding, the majority of sales growth is 
attributed to an increasing uptake of targeted cancer drugs. The sales share of targeted 
cancer therapies in the US oncology market increased from 36% in 2004 to 56% in 
2008. Among targeted cancer therapies, majority (more than 75%) of uptake belongs 
to monoclonal antibodies. CONCLUSIONS: The usage and sales trends show a sig-
niﬁ cant increase in the use of cancer drugs. The high usage of targeted cancer therapies 
versus chemotherapies shows the rapidly changing nature of cancer treatment 
regimen.
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OBJECTIVES: This paper examines how different payers and health technology 
assessment (HTA) agencies recognize and reward innovation, using treatments for 
breast and colorectal cancer as case studies. METHODS: Breast and colorectal 
cancer were chosen given the extent of clinical advancements to date and supporting 
publicly available data. Sixteen cancer medicines across these two tumor types were 
considered. For each medicine/indication, the reimbursement decision and the reasons 
behind it were obtained from assessment reports published by the respective agencies 
in Australia, Canada, England and Wales, France, and Scotland. RESULTS: Seventy-
seven decisions were reviewed (39 and 38 for breast and colorectal cancer, respec-
tively). Twenty-four (62%) and 16 (42%) were positive for breast and colorectal 
cancer, respectively, while 21% and 45% were negative. In general, HTA agencies 
appear to consider advancements in breast cancer treatments as representing good 
uses of health-care resources with some assessments yielding less positive or more 
restrictive results. The majority of appraisals for newer colorectal cancer treatments 
have failed to receive positive recommendations. CONCLUSIONS: We identiﬁ ed some 
broad areas where differences of approach have led to different decisions. These relate 
to the: 1) acceptability of surrogate end points (e.g., progression-free survival) in cases 
where improvement in overall survival has not been established; 2) extent to which 
agencies formally consider input from clinical and patient representative organizations 
as part of their decision-making process; 3) methods used to assess medicines where 
pivotal trial did not use a comparator reﬂ ecting standard therapy; and 4) mechanisms 
for re-review or adopting performance-based risk-sharing arrangements following 
rejection due to uncertain clinical and/or cost-effectiveness. Addressing these issues 
may improve the likelihood of innovative medicines meeting reimbursement require-
ments, for breast and colorectal cancer as well as other therapeutic areas, thereby 
increasing the overall health beneﬁ t from pharmaceutical development that accrue to 
patients.
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OBJECTIVES: The objective of this study was to compare HTA recommendations 
for cancer drug technologies issued by both Agency for Health Technology 
Assessment (AHTAPol) in Poland and National Institute for Health and Clinical 
Excellence (NICE) in the UK. METHODS: The review of HTA recommendations 
concerning cancer technologies published online in the period August 2007–June 2010 
(AHTAPol) and March 2000–June 2010 (NICE) was performed. The classiﬁ cation of 
HTA recommendations based on Raftery’s approach labeling them as positive, posi-
tive with major or minor restriction, and negative was conducted. Negative guidance 
was categorized as clinical or nonclinical. Reasons for HTA recommendations for drug 
technologies appraised by both AHTAPoL and NICE were compared. Contradictory 
and noncontradictory recommendations were identiﬁ ed as well. RESULTS: A total of 
149 drug technologies were appraised by AHTAPol, of which 39 concerned cancer 
technologies (seven resubmissions). NICE published 136 drug appraisals, of which 59 
related to cancer technologies (12 resubmissions). In total, 12 cancer drug technologies 
were appraised by both AHTAPoL and NICE. Among them, there were nine contra-
dictory and three noncontradictory pairs of guidance (two negative and one positive). 
In the group of drug technologies appraised by both agencies, there were 42% and 
67% positive HTA recommendations issued by AHTAPoL and NICE, respectively. 
Negative recommendations based on nonclinical reasons prevailed in Poland (58%). 
At the same time, there were as many positive recommendations with major restric-
tions (33%) as negative recommendations based on nonclinical reason (33%) in the 
UK. The positive guidance without restriction constituted 8% and 17% of all apprais-
als for cancer drug technologies published by AHTAPol and NICE, respectively. 
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CONCLUSIONS: In a studied period, NICE published more positive recommenda-
tions for cancer drug technologies than AHTAPoL. The contradictory 
recommendations prevailed in the group of drug technologies appraised by both 
jurisdictions.
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OBJECTIVES: To develop targeted leaﬂ ets regarding cancer screening guidelines that 
take account the knowledge required by different target groups. METHODS: Before 
developing leaﬂ ets, public interest data regarding cancer screening were collected by 
the problem solving model (the so-called KJ method developed for ﬁ eld surveys in 
Japan). The KJ method includes two steps: label making of information corresponded 
to speciﬁ c issues and grouping similar concepts. Contents of leaﬂ ets were edited based 
on the results of the KJ methods but changed in the ﬁ nal version according to discus-
sions at a committee meeting involving public members. We compared the results of 
the KJ method and contents of the ﬁ nal version of the leaﬂ ets for the following groups: 
cervical cancer screening targeted at 20-year-old subjects (ﬁ rst group), cervical cancer 
screening targeted at subjects aged 30 years and older (second group), and 
colorectal cancer screening targeted at subjects aged 40 years and older (third 
group). RESULTS: Common interests among the three groups included targeting 
cancer and screening methods. Although the KJ method revealed that the ﬁ rst 
group expected broad information, in the ﬁ nal version of the leaﬂ et, only basic infor-
mation regarding participation in cancer screening programs remained. The ﬁ nal 
versions in group 2 and 3 almost corresponded to the ﬁ rst interest of an actual plan 
to participate in a screening program including details of the screening methods as 
well as physical and ﬁ nancial burden expected. Although information regarding the 
harm of cancer screening was initially included according to the results of the KJ 
methods in the second and third groups, there was no expectation in the ﬁ rst group. 
CONCLUSIONS: A targeted leaﬂ et is a powerful tool to share knowledge regarding 
cancer screening. We must understand the expectations of different target groups and 
prepare appropriate leaﬂ ets that support the decision to take part in cancer 
screening.
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REASONS FOR DISCONTINUATION OF HORMONAL THERAPY IN 
BREAST CANCER PATIENTS ACROSS FIVE EUROPEAN COUNTRIES
Petrilla AA, Ferruﬁ no CP
IMS Health, Falls Church, VA, USA
OBJECTIVES: Recent evidence suggests that many breast cancer patients discontinue 
their hormonal therapy treatment regimen before the end of the recommended treat-
ment period, but reasons for treatment discontinuation are not well understood. 
Therefore, we examined reasons for hormonal therapy discontinuation in a European 
treatment cohort of female breast cancer (BC) patients. METHODS: Female patients 
ages 21+ with a diagnosis of BC between January 2006 and December 2008 were 
identiﬁ ed within IMS Oncology AnalyzerTM which provides retrospective, cross-sec-
tional, cancer-treatment data from 14 countries including France, Germany, Italy, 
Spain, and the United Kingdom and encompasses over 60,000 de-identiﬁ ed BC patient 
records from a physician panel of nearly 800 doctors in the EU5. Patients within the 
EU5 with early-stage BC (stages I-IIIa) who received hormonal therapy and for whom 
their physician provided a reason for discontinuing ﬁ rst course of therapy were 
included in the study. Patients enrolled in clinical trials were excluded. Reasons for 
discontinuation of therapy include course completion, progression of disease, stabiliza-
tion of disease, adverse events, terminal outlook, poor performance, and patient’s 
choice. RESULTS: 10,949 patients were identiﬁ ed. Approximately 57.2% discontin-
ued their ﬁ rst course of hormonal therapy prior to course completion. Of these 
patients, the top reasons for early discontinuation included progression of the disease 
(59.5%), adverse events (21.7%) and patient choice (10.1%). Mean duration of 
therapy for all patients was 95.4 months (range 45.5–152.1). Time to discontinuation 
was signiﬁ cantly shorter for those who quit due to Aes than those who quit by choice 
(36.2 months vs. 57.8 months, P < 0.0001). Of patients that discontinued due to AEs, 
hot ﬂ ushes (46.1%), pain (19.1%), and nausea and vomiting (14.0%) were the most 
commonly reported events. CONCLUSIONS: This analysis in a real world setting 
provides new insight into reasons for early discontinuation of hormonal therapy in 
the EU5.
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OBJECTIVES: The 21-gene Recurrence Score® (RS) is a validated assay for estimating 
a woman’s recurrence risk and chemotherapy beneﬁ t after the diagnosis of estrogen 
receptor positive (ER+), ESBC. We conducted a meta-analysis of RS’s inﬂ uence on 
treatment recommendations/decisions in lymph node negative (LN-) disease. 
METHODS: Literature was abstracted on cohort studies that reported the change in 
the recommendation or actual use of adjuvant chemotherapy (CT) for patients with 
ER+, LN-, ESBC before and after the RS. Outcomes evaluated were: treatment decision 
change from 1) CT plus hormone therapy (HT) to HT-only or 2) HT-only to CT plus 
HT. Actual treatment change was used when available. Reductions in the relative and 
absolute CT use associated with the RS were computed with Review Manager (5 
Version 5.0.24; Copenhagen: The Nordic Cochrane Centre, the Cochrane Collabora-
tion 2008). The relative change in CT was calculated as a before-to-after ratio of 
proportion of patients recommended or received CT, weighted by study sample size. 
RESULTS: Seven published studies (n = 912 patients) were eligible for the meta-
analysis. One was a prospective physician survey; six were retrospective chart reviews. 
a total of 569 (62%) patients were recommended CT prior to RS testing. After RS 
testing, 272 (30%) patients were recommended or received CT. In six of seven studies 
(n = 652 patients) that reported a treatment change, 212 (32%) patients switched from 
CT plus HT before RS to HT-only after RS. The absolute reduction in CT before and 
after RS testing was 30% (95% CI [−39%, −21%]). The relative reduction in CT 
before and after RS was 49% (95% CI [42%, 58%]). Estimates varied little when 
analysis omitted a single study. Limitations include heterogeneity in study designs. 
CONCLUSIONS: The meta-analysis shows consistent overall reduction in CT with 
the use of RS. 
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BACKGROUND: Retrospective claims databases are commonly used in outcomes 
research. Since physician charts are rarely available to conﬁ rm diagnoses, care must 
be taken when choosing patient populations. OBJECTIVES: To show how patient 
selection criteria affects sample size and chemotherapy treatment rates using an 
ovarian cancer (OC) population. METHODS: Patients were initially selected if 
they met the following inclusion criteria: at least one diagnosis of OC (ICD-9-CM 
codes 183.0x) between 1/1/2002 and 12/31/2007 (ﬁ rst OC diagnosis date termed 
index), 6 months pre-index and 12 months post-index eligibility, and no OC diagnosis 
in the 6 months pre-index. Additional criteria were imposed to further reﬁ ne the 
sample and assess variations in chemotherapy treatment rates. First, patients were 
required to have at least two diagnoses of OC at least 14 days apart. Next, patients 
were required to have both OC diagnoses on a record labeled as medical, surgical, 
facility, or pharmacy (i.e., ancillary records were excluded). RESULTS: A total of 
37,172 patients had at least one diagnosis of OC. Of those, 16,418 had 6 months 
pre-index and 12 months post-index eligibility with no pre-index OC diagnoses. In 
this population, 26% of patients received chemotherapy. When patients were also 
required to have one additional OC diagnosis at least 14 days from index, the sample 
size dropped to 7431 patients, of whom 47% received chemotherapy. When OC 
diagnoses on ancillary records were excluded, a total of 6213 patients were identiﬁ ed, 
of whom 52% received chemotherapy. CONCLUSIONS: Chemotherapy rates among 
OC patients varied signiﬁ cantly by the sample selection criteria used. Care must be 
taken to identify the correct patient sample in any retrospective database analysis since 
selection criteria affect the appropriateness of the sample, and thus the study 
results.
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OBJECTIVES: To provide an overview on published decision-analytic models evaluat-
ing various treatment strategies in chronic myeloid leukemia (CML). We sought to 
describe and analyze the structural and methodological approaches used and to derive 
recommendations for future CML models. METHODS: We performed a systematic 
literature review in electronic databases (Medline/PreMedline, EconLit, EMBASE, and 
others) to identify published studies evaluating CML treatment strategies using math-
ematical decision models. The models were required to compare different treatment 
strategies and to comprise relevant clinical health outcomes such as life-years gained 
or QALYs over a deﬁ ned time horizon and population. We used standardized forms 
for data extraction, description of study design, methodological framework, and data 
sources. RESULTS: We identiﬁ ed 14 different decision-analytic modeling studies, 
among which, 13 included economic evaluations. The modeling approaches varied 
substantially and comprised decision trees, Markov models, Monte Carlo simulations, 
and mathematical equations. Time horizons ranged from 2 years to lifetime. Health 
outcomes included survival, life expectancy, and QALYs. Compared treatment strate-
gies comprised bone or blood marrow transplantation, conventional chemotherapy, 
interferon-alpha, and ﬁ rst-generation tyrosine kinase inhibitor (TKI) imatinib. None 
of the models evaluated comprehensive personalized medicine strategies or second 
generation TKI (e.g., nilotinib, dasatinib). Only few models were validated using 
